Key Points
- Insider purchase: Harold Eugene Brakewood bought 5,250 shares on Jan. 16 at $4.76 each for $24,990, increasing his stake 90.52% to 11,050 shares (about $52,598).
- Immuneering is a clinical-stage, AI-driven biotech with lead program IRX-2 in Phase 2 for painful diabetic peripheral neuropathy; the company reported a quarterly loss of ($0.38) per share and has a market cap of roughly $313 million.
- Institutional investors own 67.65% of the stock with several funds recently adding to positions, and analysts show a consensus Moderate Buy rating with an average price target of $16.50.
Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Harold Eugene Brakewood bought 5,250 shares of the business's stock in a transaction on Friday, January 16th. The shares were acquired at an average price of $4.76 per share, for a total transaction of $24,990.00. Following the completion of the purchase, the insider owned 11,050 shares in the company, valued at approximately $52,598. The trade was a 90.52% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.
Immuneering Stock Up 1.5%
NASDAQ IMRX opened at $4.85 on Thursday. Immuneering Corporation has a twelve month low of $1.10 and a twelve month high of $10.08. The firm has a market cap of $313.16 million, a price-to-earnings ratio of -2.72 and a beta of 0.48. The business has a 50-day moving average price of $6.25 and a 200-day moving average price of $5.83.
Immuneering (NASDAQ:IMRX - Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). Research analysts expect that Immuneering Corporation will post -1.86 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Palumbo Wealth Management LLC increased its holdings in Immuneering by 29.0% in the 4th quarter. Palumbo Wealth Management LLC now owns 63,273 shares of the company's stock worth $416,000 after acquiring an additional 14,221 shares in the last quarter. Future Financial Wealth Managment LLC lifted its position in shares of Immuneering by 260.0% in the fourth quarter. Future Financial Wealth Managment LLC now owns 18,000 shares of the company's stock valued at $118,000 after acquiring an additional 13,000 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in Immuneering in the 3rd quarter valued at $717,000. CIBC Private Wealth Group LLC raised its position in shares of Immuneering by 233.7% in the third quarter. CIBC Private Wealth Group LLC now owns 50,051 shares of the company's stock valued at $350,000 after buying an additional 35,051 shares during the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Immuneering in the third quarter valued at approximately $350,000. Hedge funds and other institutional investors own 67.65% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $11.00 target price on shares of Immuneering in a research report on Tuesday, September 30th. Wall Street Zen downgraded shares of Immuneering from a "hold" rating to a "sell" rating in a research note on Saturday, December 20th. Oppenheimer boosted their price target on Immuneering from $21.00 to $30.00 and gave the stock an "outperform" rating in a research report on Thursday, September 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immuneering in a report on Monday, December 29th. Finally, Leerink Partners initiated coverage on Immuneering in a research report on Friday, October 31st. They set an "outperform" rating and a $15.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Immuneering presently has a consensus rating of "Moderate Buy" and an average price target of $16.50.
Get Our Latest Research Report on IMRX
About Immuneering
(
Get Free Report)
Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.
The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
